Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes

Journal of Pharmaceutical Sciences

Volumn 85, Issue 11, 1996, Pages 1180-1185

  Cotreau Bibbo, Monette M ^a   Von Moltke, Lisa L ^a   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETONE; ALPRAZOLAM; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; DRUG METABOLITE; MACROGOL; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; HUMAN; HUMAN TISSUE; LIVER MICROSOME; TRANQUILIZING ACTIVITY; XENOBIOTIC METABOLISM;

EID: 0029807016     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1021/js9601849     Document Type: Article

References (39)

1. von Moltke, L. L.; Greenblatt, D. J.; Harmatz, J. S.; Duan, S. X.; Harrel, L. M.; Cotreau-Bibbo, M. M.; Pritchard, G. A.; Wright, C. E.; Shader, R. I. Triazolam biotransformation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 1996, 276, 370-379.
2. von Moltke, L. L.; Greenblatt, D. J.; Cotreau-Bibbo, M. M.; Duan, S. X.; Harmatz, J. S.; Shader, R. I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J. Pharmacol. Exp. Ther. 1994, 268, 1278-1283.
3. von Moltke, L. L.; Greenblatt, D. J.; Duan, S. X.; Harmatz, J. S.; Shader, R. I. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J. Clin. Pharmacol. 1994, 34, 1222-1227.
4. Jordan, V. C.; Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev. 1990, 11, 49-81.
5. Nayfield, S.G.; Karp, J. E.; Ford, L. G.; Andrew, D.; Kramer, B. S. Potential role of tamoxifen in prevention of breast cancer. J. Natl. Cancer Inst. 1991, 83, 1450-1459.
6. Jordan, V. C.; Parker, C. J.; Marrow, M. Update: Breast cancer treatment and prevention with antiestrogens in the 1990's. Endocr. Rev. 1993, 1, 82-85.
7. Mani, C.; Hodgson, E.; Kupfer, D. Metabolism of the antimammary cancer antiestrogen agent tamoxifen: II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos. 1993, 21, 657-661.
8. Poon, G. K.; Chui, Y. C.; McCague, R.; Lonning, P, E.; Feng, R.; Rowlands, M. G.; Jarman, M. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab. Dispos. 1993, 21, 1119-1124.
9. Jacolot, F.; Simon, I.; Dreano, Y.; Beaune, P.; Riche, C.; Berthou, F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem . Pharm. 1991, 41, 1911-1919.
10. Mani, C.; Gelboin, HV.; Park, SS.; Pearce, R.; Parkinson, A.; Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen: I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab. Dispos. 1993, 21, 645-656.
11. Lien, E. A.; Solheim, E.; Ueland, P. M. Distribution of tamoxifen and its metabolites in rat and human tissues during steadystate treatment. Cancer Res. 1991, 51, 4837-4844.
12. van den Koedijk, C. D. M. A.; Blankenstein, M. A.; Thijssen, J. H. H. Speculation on the mechanism of action of triphenylethylene antioestrogens. Biochem. Pharm. 1994, 11, 1927-1937.
13. Coezy, E.; Borgna, J.-L.; Rochefor,t H. Tamoxifen and metabolites in MCF7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 1982, 42, 317-323.
14. Jordan, V. C.; Collins, M. M.; Rowsby, L.; Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocr. 1977, 75, 305-315.
15. Buckley, M. M.-T.; Goa, K. L. Tamoxifen: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 1989, 37, 451-490.
16. 3H]4-hydroxytamoxifen, an active antiestrogen metabolite. Mol. Cell. Endocrinol. 1980, 20, 71-85.
17. Blankson, E. A.; Ellis, S. W.; Lennard, M. S.; Tucker, G. T.; Rogers, K. The metabolism of tamoxifen by human liver microsomes is not mediated by cytochrome P450IID6. Biochem. Pharm. 1991, 42, S209-S212.
18. von Moltke, L. L.; Greenblatt, D. J.; Harmatz, J.S.; Shader, R. I. Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993, 47, 268-276.
19. von Moltke, L. L.; Greenblatt, D. J.; Cotreau-Bibbo, M. M.; Harmatz, J. S.; Shader, R. I. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br. J. Clin. Pharmacol. 1994, 38, 23-31.
20. von Moltke, L. L.; Greenblatt, D. J.; Duan, S. X.; Schmider, J.; Kudchadker, L.; Fogelman, S. M.; Harmatz. J. S.; Shader, R. I. Phenacetin O-deethylation by human liver microsomes in vitro: Inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology, in press.
21. Schmider, J.; Greenblatt, D. J.; Harmatz, J. S.; Shader, R. I. Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br. J. Clin. Pharmacol. 1996, 41, 593-604.
22. Court, M. H.; von Moltke, L. L.; Shader, R. I.; Greenblatt, D. J. In vitro chlorzoxazone 6-hydroxylation and inhibition by diethyldithiocarbamate: A comparative study using hepatic microsomes from humans and 10 other mammalian species. Biopharm. Drug Disp., in press.
23. Berthou, F.; Dreano, Y. High-performance liquid Chromatographic analysis of tamoxifen, toremifene and their major human metabolites. J. Chromatogr. 1993, 616, 117-127.
24. Schmider, J.; Greenblatt, D. J.; von Moltke, L. L.; Harmatz, J. S.; Shader, R. I. N-demetoylation of amitriptyline in vitro: Role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J. Pharmacol. Exp. Ther. 1995, 27, 592-597.
25. Lim, C. K.; Yuan, Z.-X.; Lamb, J. H.; White, I. N. H.; De Matteis, F.; Smith, L. L. Study of tamoxifen metabolism in female rat, mouse and human microsomes. Carcinogenesis 1994, 15, 589-593.
26. Lim, C. K.; Chow, L. C. L.; Yuan, Z.-X.; Smith, L. L. High performance liquid chromatography of tamoxifen and metabolites in plasma and tissues. Biomed. Chromatogr. 1993, 7, 311-314.
27. Hoope, W. D.; Watt, J. A.; McKinnon, G. E.; Reilly, P. E. B. Metabolism of diazepam and related benzodiazepines by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 1992, 17, 51-59.
28. Anders, M. W. Acetone enhancement of microsomal aniline parahydroxylase activity. Arch. Biochem. Biophys. 1968, 126, 269-275.
29. Lu, A. Y. H.; Jacobson, M.; Levin, W.; West, S. B.; Kuntzman, R. Reconstituted liver microsomal enzyme system that hydroxylates drugs, other foreign compounds, and endogenous substrates. Arch. Biochem. Biophys. 1972, 153, 294-297.
30. Kitada, M.; Hasunuma, Y.; Rikihisa, T.; Kanakubo, Y. Enhancement of aniline hydroxylation in human liver microsomes. Res Commun. Chem. Pathol. Pharmacol. 1986, 51, 101-116.
31. Kronbach, T.; Mathys, D.; Umeno, M.; Gonzalez, F. J.; Meyer, U. A. Oxidation of midazolam and triazolam by human liver cytochrome P450 IIIA4. Mol. Pharmacol. 1989, 36, 89-96.
32. Kobusch, A. B.; Plaa, G. L.; du Souich, P. Effects of acetone and methyl n-butyl ketone on hepatic mixed-function oxidase. Biochem. Pharm. 1989, 38, 3461-3467.
33. Schwab, G. E.; Raucy, J. L.; Johnson, E. F. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol. Pharmacol. 1988, 33, 493-499.
34. Andersson, T.; Miners, J. O.; Veronese, M. E.; Birkett, D. J. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Br. J. Clin. Pharmacol. 1994, 38, 131-137.
35. Shou, M.; Grogan, J.; Mancewicz, J. A.; Krausz, K. W.; Gonzalez, F. J.; Gelboin, H. V.; Korzekwa, K. R. Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 1994, 33, 6450-6455.
36. Koley, A. P.; Robinson, R. C.; Markowitz, A.; Friedman, F. K. Interaction of polycyclic aromatic hydrocarbons and flavones with cytochromes P450 in the endoplasmic reticulum: Effect on CO binding kinetics. Biochemistry 1995, 34, 1942-1947.
37. Siess, M.-E.; Leclerc, J.; Canivenc-Lavier, M.-C.; Rat, P.; Suschetet, M. Heterologous effects of natural flavonoids on monooxygenase activities in human and rat liver microsomes. Toxicol. Appl. Pharmacol. 1995, 130, 73-78.
38. Johansson, I.; Ekstrom, G.; Scholte, B.; Puzycki, D.; Jornvall, H.; Ingelman-Sundberg, M. Ethanol-, fasting-, and acetone-inducible cytochromes P-450 in rat liver: regulation and characteristics of enzymes belonging to the IIB and IIE gene subfamilies. Biochemistry 1988, 27, 1925-1934.
39. Kurata, N.; Hurst, H. E.; Benz, F. W.; Kemper, R. A.; Waddell, W. J. Studies on inhibition and induction of metabolism of ethyl carbamate by acetone and related compounds: Evidence for metabolism of cytochromes P-450. Drug Metab. Dispos. 1991, 19, 388-393.